AIM ImmunoTech Reports 100% Ebola Survival in Mice at 6 mg/kg Dose
AIM•AIM ImmunoTech’s Ampligen achieved 100% survival in a Biosafety Level 4 mouse study at a 6 mg/kg dose following lethal Ebola infection. The company will host a virtual investor presentation on June 4 detailing these findings as global health authorities declare the Bundibugyo outbreak a public health emergency.
1. Preclinical Efficacy Demonstrated in Mouse Model
In a Biosafety Level 4 study at USAMRIID, Ampligen administered at 6 mg/kg post-infection delivered 100% survival in mice exposed to a typically lethal Ebola virus dose, demonstrating both prophylactic and early-intervention potential through TLR3 activation and VP35 dsRNA binding blockade.
2. Investor Briefing Scheduled for June 4
On June 4 at 9 AM ET, AIM ImmunoTech will release an on-demand video presentation titled “Ebola: What This Means,” reviewing Ampligen’s mechanism of action, preclinical findings and potential development pathways for Ebola virus disease preparedness.
3. Strategic and Regulatory Outlook
With the Bundibugyo outbreak declared a public health emergency and no approved treatments available, Ampligen’s FDA and EMA orphan drug designations position the company to pursue global health authority engagements, potential biodefense partnerships and expanded Biosafety Level 4 research collaborations.
